Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
17.98
-0.46 (-2.49%)
Apr 29, 2026, 9:48 AM EDT - Market open
Caris Life Sciences Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Caris Life Sciences stock have an average target of 30.91, with a low estimate of 21 and a high estimate of 42. The average target predicts an increase of 71.91% from the current stock price of 17.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Caris Life Sciences stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 5 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 9 | 9 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +55.73% | Apr 13, 2026 |
| Piper Sandler | Piper Sandler | Hold Initiates $21 | Hold | Initiates | $21 | +16.80% | Apr 10, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $34 → $30 | Buy | Maintains | $34 → $30 | +66.85% | Apr 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $30 → $22 | Hold | Maintains | $30 → $22 | +22.36% | Mar 13, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $38 → $34 | Buy | Maintains | $38 → $34 | +89.10% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
1.02B
from 812.03M
Increased by 25.24%
Revenue Next Year
1.24B
from 1.02B
Increased by 22.32%
EPS This Year
0.13
from -3.22
EPS Next Year
0.37
from 0.13
Increased by 193.11%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.1B | 1.4B | ||||||
| Avg | 1.0B | 1.2B | ||||||
| Low | 980.0M | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 30.9% | 33.2% | ||||||
| Avg | 25.2% | 22.3% | ||||||
| Low | 20.7% | 13.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.36 | 0.56 | |||
| Avg | 0.13 | 0.37 | |||
| Low | 0.02 | 0.14 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 340.2% | |||
| Avg | - | 193.1% | |||
| Low | - | 8.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.